Most secretory proteins travel through a well-documented conventional secretion pathway
involving the endoplasmic reticulum (ER) and the Golgi complex. However, recently, it has …

Essential thrombocythemia (ET) is an acquired myeloproliferative disorder (MPD)
characterized by a sustained elevation of platelet number with a tendency for thrombosis …

Background Polycythemia vera, essential thrombocythemia, and idiopathic myelofibrosis are
clonal myeloproliferative disorders arising from a multipotent progenitor. The loss of …

The analysis of rare chromosomal translocations in myeloproliferative disorders has
highlighted the importance of aberrant tyrosine kinase signaling in the pathogenesis of …

Summary Background An acquired V617F mutation in JAK2 occurs in most patients with
polycythaemia vera, but is seen in only half those with essential thrombocythaemia and …

An acquired somatic mutation in the JAK2 gene (JAK2-V617F) is present in the majority of
patients with myeloproliferative disorders (MPDs). Several phenotypic manifestations …

1Department of Haematology, Queen's University, Belfast, Belfast City Hospital, Belfast,
2Department of Haematology, City Hospital, Birmingham, 3Department of Haematology …

The diagnosis of an underlying chronic myeloproliferative disorder (CMPD) is often
problematic in patients with primary extrahepatic portal vein obstruction (EHPVO) or Budd …

An acquired gain-of-function mutation in the Janus kinase 2 (JAK2-V617F) is frequently
found in patients with myeloproliferative disorders (MPDs). To test the hypothesis that JAK2 …

Somatic mutations in TET2 occur in patients with myeloproliferative neoplasms and other
hematologic malignancies. It has been suggested that TET2 is a tumor suppressor gene and …